EUVIMEDOpdag EUVIMED
Crossref

Silencing drug transporters in human primary muscle cells modulates atorvastatin pharmacokinetics: A pilot study

Emilia Hoste, Louise Deldicque, Giulio G Muccioli iD, Nadtha Panin, Romano Terrasi, Adrien Paquot, Maxime Lingurski, Sébastien Pyr Dit Ruys, Vincent Haufroid, Laure Elens iD

British Journal of Pharmacology · 2025-05 · 182 (9) · 2049-2066

DOI: 10.1111/bph.17449 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2025-02-05. Written by Emilia Hoste and 9 co-authors. Institution: Integrated PharmacoMetrics, PharmacoGenomics and PharmacoKinetics, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvai…. Major MEDLINE topics: Atorvastatin, Muscle Fibers, Skeletal, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Cited 4 times so far (Crossref); 46 references. Funded by: Fonds pour la Formation à la Recherche dans l''Industrie et dans l''Agriculture, Bourse du Patrimoine, Fonds national de la Recherche scientifique.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Non‐adherence to atorvastatin treatment is relatively common and partly due to statin‐related myotoxicities (SRMs). The risk of developing SRM is dose‐ and concentration‐dependent, highlighting the importance of atorvastatin pharmacokinetics. This study explored the inter‐individual variabilities in expression of the atorvastatin transporter gene contributing to modulation of atorvastatin within the muscle cell. Experimental Approach mRNA levels of efflux and influx transporters were measured and modulated with siRNAs to evaluate effects on intracellular accumulation of atorvastatin in primary cultures of differentiated myotubes from 12 human volunteers. Key Results All genes assessed were expressed with a high inter‐individual variability. In differentiated myotubes, efflux transporters were expressed at higher levels than the influx carriers. When considering efflux and influx transporters separately, ABCC1 and SLCO2B1 are the most highly expressed efflux and influx transporters. Suppression of ABCC1 , ABCC4 and/or ABCG2 mRNA levels with siRNA significantly increased intracellular accumulation of atorvastatin in differentiated myotubes. Interestingly, the siRNA targeting ABCG2 had a moderate effect on intracellular accumulation of atorvastatin in a volunteer expressing the ABCG2 variant rs2231142 (c.421C>A, p.Gln141Lys). This hypothesis was further validated in a HEK recombinant model overexpressing ABCG2 either wild‐type (421C) or variant (421A). Reduction of SLCO1B1 and SLCO2B1 mRNA levels significantly modified intracellular accumulation of atorvastatin in only some volunteers, depending on the expression levels of transporters. Conclusion and Implications Silencing ABCC1 , ABCC4 or ABCG2 expression alters accumulation of atorvastatin in myotubes, whereas the effect of silencing influx transporters depends on the expression of these transporters.

Subjects

MeSH terms (MEDLINE)

AtorvastatinMuscle Fibers, SkeletalHydroxymethylglutaryl-CoA Reductase InhibitorsHumansPilot ProjectsCells, CulturedATP-Binding Cassette, Sub-Family C ProteinsGene SilencingMaleRNA, Small InterferingATP Binding Cassette Transporter, Subfamily G, Member 2RNA, MessengerOrganic Anion TransportersAdultNeoplasm ProteinsFemaleMembrane Transport Proteins

Author keywords

efflux transporterinflux transporterinhibitorsinter‐individual variabilityprimary human skeletal muscle cell cultures

Substances

AtorvastatinATP-Binding Cassette, Sub-Family C ProteinsHydroxymethylglutaryl-CoA Reductase InhibitorsRNA, Small InterferingATP Binding Cassette Transporter, Subfamily G, Member 2RNA, MessengerOrganic Anion TransportersNeoplasm ProteinsMembrane Transport Proteinsmultidrug resistance-associated protein 1

Authors and institutions

  • Integrated PharmacoMetrics, PharmacoGenomics and PharmacoKinetics, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Louvain Centre for Toxicology and Applied Pharmacology, Institut de recherche expérimentale et clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Institute of Neuroscience (IoNS), Université catholique de Louvain (UCLouvain), Louvain-la-Neuve, Belgium.
  • Bioanalysis and Pharmacology of Bioactive Lipids, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Department of Clinical Chemistry, Cliniques universitaires Saint-Luc, Brussels, Belgium.

ORCID profiles: Giulio G Muccioli, Laure Elens

Funding

  • Fonds pour la Formation à la Recherche dans l''Industrie et dans l''Agriculture
  • Bourse du Patrimoine
  • Fonds national de la Recherche scientifique

Cite

APA

Hoste, E., Deldicque, L., Muccioli, G. G., Panin, N., Terrasi, R., Paquot, A., Lingurski, M., Pyr Dit Ruys, S., Haufroid, V., & Elens, L. (2025). Silencing drug transporters in human primary muscle cells modulates atorvastatin pharmacokinetics: A pilot study. British Journal of Pharmacology, 182(9), 2049-2066. https://doi.org/10.1111/bph.17449

Vancouver

Hoste E, Deldicque L, Muccioli GG, Panin N, Terrasi R, Paquot A, et al. Silencing drug transporters in human primary muscle cells modulates atorvastatin pharmacokinetics: A pilot study. British Journal of Pharmacology. 2025;182(9):2049-2066. doi:10.1111/bph.17449

BibTeX
@article{Hoste2025,
  author = {Hoste, Emilia and Deldicque, Louise and Muccioli, Giulio G and Panin, Nadtha and Terrasi, Romano and Paquot, Adrien and Lingurski, Maxime and Pyr Dit Ruys, Sébastien and Haufroid, Vincent and Elens, Laure},
  title = {Silencing drug transporters in human primary muscle cells modulates atorvastatin pharmacokinetics: A pilot study},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {9},
  pages = {2049--2066},
  doi = {10.1111/bph.17449}
}
Start for free →